LTO1 Antibody

What is the molecular structure and function of LTO1?

LTO1 (Protein LTO1 homolog) contains a distinctive deca-GX3 motif of 40 residues that is not found in any other eukaryotic protein. This structural element is critical for its function, along with a conserved C-terminal tryptophan (phenylalanine in some organisms) . Functionally, the LTO1:YAE1 complex serves as a target-specific adapter that recruits apo-ABCE1 to the cytosolic iron-sulfur protein assembly machinery.

The protein plays several important roles:

• Biogenesis of the large ribosomal subunit

• Initiation of translation

• Regulation of proline metabolism

• Production of reactive oxygen species (ROS)

Mutational studies have shown that the deca-GX3 domain is crucial for LTO1 complex formation with both YAE1 and the CIA targeting complex, while the C-terminal tryptophan is specifically required for interaction with the CIA targeting complex .

What types of LTO1 antibodies are available for research applications?

Researchers have access to several types of LTO1 antibodies with the following characteristics:

These antibodies are typically generated against specific epitopes, such as the 81-130 amino acid region of the human LTO1 protein . They undergo affinity purification using epitope-specific immunogens to ensure specificity. For research applications, recommended dilution ranges vary by technique:

• Western Blot: 1:500-1:2000

• Immunohistochemistry: 1:100-1:300

• Immunofluorescence: 1:200-1:1000

• ELISA: 1:10000

How does LTO1 compare to its homologs across different species?

The LTO1 protein shows evolutionary conservation but with notable species-specific differences. In yeast studies, researchers identified YAE1D1 and ORAOV1 as the human homologs of yeast Yae1 and Lto1, respectively . Interestingly, neither human protein alone could restore growth defects in yeast cells depleted of their counterparts, but co-expression of both human proteins successfully complemented the growth defect .

Sequence analysis revealed that S. cerevisiae Lto1 contains an unusual N-terminal extension of 36 amino acid residues not present in other Lto1 homologs. Experimental evidence including ribosome foot-printing data and mutational studies confirmed that this extension is not essential for function, suggesting that the physiologically correct translation start site is located 108 bp downstream of the previously annotated start codon .

The conservation of critical functional elements, particularly the deca-GX3 motif and C-terminal tryptophan, highlights their evolutionary importance across species despite other sequence variations.

What are best practices for using LTO1 antibodies in Western blot analysis?

For optimal Western blot results with LTO1 antibodies, researchers should follow this methodological approach:

Sample Preparation:

• Lyse cells or tissues in RIPA buffer supplemented with protease inhibitors

• Determine protein concentration (Bradford or BCA assay)

• Load 20-50 μg total protein per lane

• Denature samples in Laemmli buffer at 95°C for 5 minutes

Electrophoresis and Transfer:

• Separate proteins on 10-12% SDS-PAGE gel

• Transfer to PVDF or nitrocellulose membrane (wet transfer recommended)

Immunoblotting:

• Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary LTO1 antibody at 1:500-1:2000 dilution overnight at 4°C

• Wash 3× with TBST, 10 minutes each

• Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Wash 3× with TBST, 10 minutes each

• Develop using enhanced chemiluminescence detection

Critical Considerations:

• Include positive control (cell line known to express LTO1)

• Include negative control (LTO1 knockdown cells if available)

• Expect detection at the predicted molecular weight of LTO1

• Allow antibody to reach room temperature before use and avoid vigorous vortexing

How can immunofluorescence techniques be optimized for LTO1 localization studies?

Immunofluorescence studies with LTO1 antibodies require careful optimization to accurately visualize the protein's subcellular localization, which has been reported as primarily nuclear .

Recommended Protocol:

• Culture cells on coverslips to 70-80% confluence

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 for 10 minutes

• Block with 5% normal serum in PBS for 1 hour

• Incubate with LTO1 primary antibody at 1:200-1:1000 dilution overnight at 4°C

• Wash 3× with PBS, 5 minutes each

• Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature

• Counterstain nuclei with DAPI

• Mount slides with anti-fade mounting medium

Validation Approaches:

• Compare staining pattern with subcellular markers

• Perform siRNA knockdown of LTO1 to confirm specificity

• Use peptide competition assays to verify epitope-specific binding

• Co-stain with YAE1 antibodies to confirm expected interaction patterns

High-quality immunofluorescence should reveal the nuclear localization of LTO1, potentially with distinct subnuclear patterns that reflect its involvement in ribosome biogenesis and translation initiation.

What methods can be used to study LTO1 protein-protein interactions?

To investigate LTO1 interactions with binding partners such as YAE1 and components of the CIA targeting complex, researchers can employ several complementary techniques:

Co-immunoprecipitation (Co-IP):

• Lyse cells under gentle conditions to preserve protein complexes

• Immunoprecipitate using LTO1 antibodies

• Analyze precipitated proteins by Western blot for suspected interaction partners

• Reverse approach: IP with antibodies against potential partners and probe for LTO1

Studies in yeast have shown that affinity purification of the Yae1-Lto1 complex with CIA proteins was significantly enhanced when cells were depleted of the early-acting CIA factor Nbp35, indicating that interaction dynamics are sensitive to cellular conditions .

Proximity Ligation Assay (PLA):

• Utilize LTO1 antibodies together with antibodies against potential interaction partners

• Perform PLA according to manufacturer's protocol

• Analyze fluorescent signals that indicate proteins in close proximity (<40 nm)

Mutational Analysis:
Research has demonstrated that mutations in LTO1's deca-GX3 domain and C-terminal tryptophan significantly impact protein interactions. Specifically, mutations at positions G33;G37;G41 and G49;G53 almost completely abrogated association with the CIA targeting complex and decreased complex formation with YAE1 . These findings provide valuable molecular targets for interaction studies.

How can LTO1 antibodies be used to investigate iron-sulfur protein biogenesis pathways?

LTO1 functions in iron-sulfur protein biogenesis through its interaction with the CIA targeting complex. Research has shown that the LTO1-YAE1 complex facilitates the maturation of specific Fe-S proteins, particularly Rli1 . To investigate this pathway:

Experimental Approach:

• Differential analysis under iron deficiency or oxidative stress conditions:

  • Treat cells with iron chelators or oxidative stress inducers

  • Compare LTO1 expression, localization, and interactions using antibodies

  • Correlate with Fe-S protein activity measurements

• Proximity-dependent biotin labeling:

  • Express BioID or APEX2 fused to LTO1

  • Identify biotinylated proteins using streptavidin pulldown followed by mass spectrometry

  • Validate interactions using LTO1 antibodies in co-IP experiments

• Analysis of Fe-S cluster transfer:

  • Radiolabel cells with 55Fe (as demonstrated in yeast studies)

  • Immunoprecipitate LTO1 and its partners using specific antibodies

  • Measure 55Fe incorporation into client proteins

The yeast research has shown that mutations within the middle or C-terminal region of LTO1's deca-GX3 motif or exchange of the C-terminal tryptophan severely impaired the maturation of the Fe-S protein Rli1 , highlighting critical functional domains that could be targeted in human studies.

What strategies can be employed to study potential post-translational modifications of LTO1?

Investigating post-translational modifications (PTMs) of LTO1 requires specialized approaches using LTO1 antibodies:

Comprehensive PTM Analysis Strategy:

• Western blot band pattern analysis:

  • Run samples on high-resolution gels (8-15% gradient) to separate potential PTM variants

  • Look for mobility shifts that might indicate phosphorylation, ubiquitination, or other modifications

  • Compare patterns before and after treatment with phosphatases or deubiquitinases

• Immunoprecipitation combined with mass spectrometry:

  • Use LTO1 antibodies to immunoprecipitate the protein from cells

  • Analyze by LC-MS/MS to identify PTMs

  • Compare PTM profiles under different cellular conditions (e.g., cell cycle stages, stress conditions)

• Phosphorylation-specific analysis:

  • Treat immunoprecipitated LTO1 with λ-phosphatase

  • Compare Western blot patterns before and after treatment

  • If available, use phospho-specific antibodies to detect specific phosphorylation events

• Correlation with function:

  • Mutate potential PTM sites and assess impact on LTO1's interaction with YAE1 and the CIA targeting complex

  • Use LTO1 antibodies to analyze how these mutations affect protein localization and complex formation

Understanding LTO1's PTM profile could provide insights into how its function in Fe-S protein biogenesis is regulated under different cellular conditions.

How can recent advances in antibody engineering be applied to enhance LTO1 research?

Recent developments in antibody technology offer new opportunities for LTO1 research:

Advanced Antibody-Based Approaches:

• Single-domain antibodies (nanobodies):

  • Develop LTO1-specific nanobodies for live-cell imaging

  • Use for super-resolution microscopy applications

  • Create intrabodies to track and manipulate LTO1 in living cells

• Antibody fragment-based proximity labeling:

  • Conjugate BioID or APEX2 to LTO1 antibody fragments

  • Map the LTO1 protein neighborhood in living cells

  • Identify condition-specific interaction partners

• Bispecific antibodies:

  • Generate antibodies recognizing both LTO1 and key interactors

  • Use to study complex assembly dynamics

  • Apply to enhance detection of specific LTO1-containing complexes

Research on designing antibodies with customized specificity profiles, as shown in reference , could be applied to develop antibodies with specific high affinity for particular LTO1 epitopes or with cross-specificity for multiple epitopes, enhancing the toolkit for LTO1 research.

What are common challenges when using LTO1 antibodies and how can they be addressed?

Researchers working with LTO1 antibodies may encounter several technical challenges:

General Troubleshooting Approach:

• Always include positive and negative controls

• Validate antibody performance with each new lot

• Optimize protocols for specific sample types

• Consider epitope availability in different applications

Proper storage and handling of LTO1 antibodies is critical for maintaining performance. Store at -20°C, avoid repeated freeze-thaw cycles by making single-use aliquots, and use within the manufacturer's recommended shelf life .

How should experimental results with LTO1 antibodies be interpreted in the context of iron-sulfur protein biogenesis?

Interpreting LTO1 antibody data in the context of Fe-S protein biogenesis requires consideration of several factors:

Interpretation Framework:

• Expression level correlations:

  • Compare LTO1 levels (by Western blot) with Fe-S protein activity

  • Look for inverse correlations with stress markers

  • Assess co-regulation with other CIA components

• Localization pattern analysis:

  • Nuclear localization may indicate function in ribosome biogenesis

  • Co-localization with CIA components suggests active involvement in Fe-S protein maturation

  • Redistribution under stress conditions may indicate pathway regulation

• Complex formation interpretation:

  • Increased association with CIA components under Fe-S protein maturation impairment, as seen in yeast studies

  • Client protein interactions (like with Rli1) may vary based on cellular iron status

• Functional impact assessment:

  • Connect observed changes in LTO1 levels/interactions with downstream effects on translation and ribosome biogenesis

  • Consider how observed phenotypes align with LTO1's dual roles in Fe-S protein maturation and translation

Understanding the complex relationships between LTO1, its binding partners, and cellular conditions requires integrating multiple lines of evidence from antibody-based experiments.

How might LTO1 antibodies contribute to cancer research?

The human LTO1 homolog, ORAOV1 (Oral Cancer-Overexpressed Protein 1), was discovered in the context of cancer research . This connection suggests promising avenues for cancer-focused LTO1 studies:

Cancer Research Applications:

• Expression profiling across tumors:

  • Use LTO1 antibodies for immunohistochemistry on tissue microarrays

  • Correlate expression with clinical parameters and outcomes

  • Assess potential diagnostic or prognostic value

• Mechanistic studies:

  • Investigate how LTO1 overexpression affects ribosome biogenesis in cancer cells

  • Study its role in modulating translation of oncogenes or tumor suppressors

  • Explore connections between LTO1, ROS production, and cancer cell metabolism

• Therapeutic targeting assessment:

  • Use LTO1 antibodies to monitor protein levels during drug treatment

  • Evaluate potential as a biomarker for response to therapies targeting protein synthesis

  • Develop inhibitors of LTO1-protein interactions and validate with antibody-based assays

The potential connections between LTO1's functions in Fe-S protein biogenesis, translation, and cancer cell growth make it an intriguing subject for cancer research using antibody-based approaches.

What emerging technologies could enhance LTO1 antibody applications in research?

Several cutting-edge technologies offer opportunities to expand LTO1 research capabilities:

Emerging Methodological Approaches:

• Single-cell proteomics:

  • Use LTO1 antibodies in mass cytometry (CyTOF) panels

  • Analyze heterogeneity of LTO1 expression at single-cell resolution

  • Correlate with other proteins in Fe-S biogenesis and translation pathways

• Super-resolution microscopy:

  • Apply techniques like STORM or STED using LTO1 antibodies

  • Map precise subnuclear localization at nanometer resolution

  • Visualize interactions with binding partners at molecular scale

• Spatial transcriptomics integration:

  • Combine LTO1 immunostaining with spatial transcriptomics

  • Correlate protein expression with local transcriptomic landscapes

  • Identify tissue microenvironments with coordinated expression patterns

• Computational antibody design:

  • Develop LTO1 antibodies with enhanced specificity using approaches like those described in reference

  • Create antibodies targeting specific conformational states or protein complexes

  • Engineer reagents for detecting specific post-translational modifications

Recent advances in inference and design of antibody specificity could be particularly valuable for developing next-generation LTO1 antibodies with customized specificity profiles for advanced research applications.